| Secondary |
| Hiv Infection |
53.2% |
| Drug Use For Unknown Indication |
14.4% |
| Product Used For Unknown Indication |
5.0% |
| Acquired Immunodeficiency Syndrome |
3.6% |
| Diffuse Panbronchiolitis |
2.9% |
| Antifungal Prophylaxis |
2.3% |
| Drug Exposure During Pregnancy |
2.3% |
| Prophylaxis |
2.0% |
| Mycobacterium Avium Complex Infection |
1.8% |
| Cerebral Toxoplasmosis |
1.5% |
| Opportunistic Infection Prophylaxis |
1.4% |
| Diarrhoea |
1.3% |
| Encephalopathy |
1.3% |
| Cytomegalovirus Infection |
1.1% |
| Fungal Infection |
1.1% |
| Depression |
1.0% |
| Drug Eruption |
1.0% |
| Tuberculosis |
1.0% |
| Anxiety |
0.9% |
| Mycobacteria Test |
0.9% |
|
| Liver Injury |
16.9% |
| Uveitis |
11.2% |
| Lymphoma |
6.7% |
| Vitamin B12 Deficiency |
6.7% |
| Angina Unstable |
5.6% |
| Completed Suicide |
5.6% |
| Platelet Count Decreased |
5.6% |
| Renal Failure Acute |
5.6% |
| Meningitis Cryptococcal |
4.5% |
| Urticaria Chronic |
4.5% |
| Cardio-respiratory Arrest |
3.4% |
| Intra-abdominal Haemorrhage |
3.4% |
| Skin Swelling |
3.4% |
| Vision Blurred |
3.4% |
| Abortion Spontaneous |
2.2% |
| Acute Hepatic Failure |
2.2% |
| Death |
2.2% |
| Haematoma |
2.2% |
| Myalgia |
2.2% |
| Myocardial Ischaemia |
2.2% |
|
| Concomitant |
| Hiv Infection |
56.7% |
| Product Used For Unknown Indication |
7.4% |
| Drug Use For Unknown Indication |
4.9% |
| Antifungal Prophylaxis |
2.9% |
| Rash |
2.6% |
| Opportunistic Infection Prophylaxis |
2.3% |
| Cytomegalovirus Infection |
2.0% |
| Prophylaxis |
2.0% |
| Diffuse Panbronchiolitis |
1.9% |
| Antiretroviral Therapy |
1.7% |
| Drug Exposure During Pregnancy |
1.7% |
| Hepatitis C |
1.7% |
| Postoperative Care |
1.7% |
| Haemophilia |
1.6% |
| Reflux Oesophagitis |
1.6% |
| Acute Myeloid Leukaemia |
1.4% |
| Depression |
1.4% |
| Gastric Ulcer |
1.4% |
| Oesophageal Ulcer |
1.4% |
| Arthritis |
1.3% |
|
| White Blood Cell Count Decreased |
16.1% |
| Premature Baby |
7.1% |
| Hepatic Failure |
5.4% |
| Jaundice |
5.4% |
| Meningitis Cryptococcal |
5.4% |
| Oesophageal Varices Haemorrhage |
5.4% |
| Thrombocytopenia |
5.4% |
| Vision Blurred |
5.4% |
| Weight Decreased |
5.4% |
| Death |
3.6% |
| Diabetes Mellitus Inadequate Control |
3.6% |
| Hyperlactacidaemia |
3.6% |
| Hyperlipidaemia |
3.6% |
| Intra-uterine Death |
3.6% |
| Lipoatrophy |
3.6% |
| Melaena |
3.6% |
| Pancytopenia |
3.6% |
| Platelet Count Decreased |
3.6% |
| Polyneuropathy |
3.6% |
| Rash |
3.6% |
|
| Interacting |
| Hiv Infection |
28.6% |
| Prophylaxis |
12.2% |
| Acute Myeloid Leukaemia |
10.2% |
| Product Used For Unknown Indication |
10.2% |
| Antiretroviral Therapy |
6.1% |
| Drug Use For Unknown Indication |
6.1% |
| Graft Versus Host Disease |
6.1% |
| Prophylaxis Against Hiv Infection |
6.1% |
| Antifungal Prophylaxis |
2.0% |
| Bacterial Infection |
2.0% |
| Bipolar Disorder |
2.0% |
| Fungal Infection |
2.0% |
| Gastrointestinal Infection |
2.0% |
| Herpes Virus Infection |
2.0% |
| Substance Use |
2.0% |
|
| Off Label Use |
25.0% |
| Drug Interaction |
12.5% |
| Hepatitis Cholestatic |
12.5% |
| Hepatobiliary Disease |
12.5% |
| Osteonecrosis |
12.5% |
| Renal Impairment |
12.5% |
| Visual Impairment |
12.5% |
|
